Alexion Europe Sas

Spain

All drugs from this manufacturer

  • KANUMA 2 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION

    It is used to treat patients of all ages who have lysosomal acid lipase deficiency (LAL deficiency), a genetic disease that causes liver damage, high cholesterol levels, and other complications due to fat accumulation.

    Dosage form: solution for infusion, concentrate

    Active substance Dosage
    sebelipase alfa 20 mg

    ATC: A16A A16AB A16AB14

  • It is used to treat several diseases: paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in patients who do not respond to other treatments, and neuromyelitis optica spectrum disorder (NMOSD).

    Dosage form: solution for infusion, concentrate

    Active substance Dosage
    eculizumab 10 mg

    ATC: L04A L04AJ L04AJ01

  • It is used to treat several diseases: paroxysmal nocturnal hemoglobinuria (PNH) in adults and children (weighing 10 kg or more), atypical hemolytic uremic syndrome (aHUS) in adults and children (weighing 10 kg or more), generalized myasthenia gravis (gMG) in adults, and neuromyelitis optica spectrum disorder (NMOSD) in adults.

    Dosage form: solution for infusion, concentrate

    Active substance Dosage
    ravulizumab 1100 mg

    ATC: L04A L04AJ L04AJ02

  • It is used to treat various diseases: paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in adults and children weighing 10 kg or more, generalized myasthenia gravis (gMG) in adults, and neuromyelitis optica spectrum disorder (NMOSD) in adults.

    Dosage form: solution for infusion, concentrate

    Active substance Dosage
    ravulizumab 300 mg

    ATC: L04A L04AJ L04AJ02

  • It is used to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who are already receiving treatment with C5 inhibitors (ravulizumab or eculizumab) and who present with residual hemolytic anemia.

    Dosage form: tablets, film-coated

    Active substance Dosage
    danicopan 100 mg

    ATC: L04A L04AJ L04AJ09

  • It is used to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who are already receiving treatment with C5 inhibitors (ravulizumab or eculizumab) and who still present with residual hemolytic anemia.

    Dosage form: tablets, film-coated

    Active substance Dosage
    danicopan 50 mg
    danicopan 100 mg

    ATC: L04A L04AJ L04AJ09